Research across Cancer
Related studies from across the Cancer family.
T cell signaling and metabolic rewiring are critical for T cell engager efficacy in solid tumors
New research explores how cell metabolism affects cancer treatments
This mini-review explores the roles of T cell signaling and metabolism in T cell engagers (TCEs) for solid tumors and hematologic malignanci…
Scientists are looking at how the energy and nutrients inside immune cells impact the success of new cancer therapies.
IEN plus NACT shows greatest improvement in CD4+ counts among ranked strategies
New research identifies ways to protect immune cells during cancer surgery
This network meta-analysis of 82 RCTs evaluates multimodal interventions to maintain T lymphocyte subsets in patients with solid tumors unde…
A new analysis shows that combining specific nutrition and therapies can help maintain vital immune cell levels for patients undergoing soli…
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors
New drugs show promise for patients with specific tumor mutations
This meta-analysis of 3 RCTs involving 949 patients evaluated KRAS G12C inhibitors for solid tumors. The analysis found a significant improv…
A new class of drugs shows promise in slowing the growth of certain solid tumors for patients with a specific genetic mutation.
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management
Combining immune checkpoint inhibitors and radiotherapy improves survival outcomes
Meta-analysis data indicates that combining immune checkpoint inhibitors with radiotherapy significantly improves survival outcomes in solid…
New data shows that adding immune checkpoint inhibitors to radiation therapy can improve survival for patients with many types of solid tumo…
Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies
New framework aims to improve treatment for solid tumors
This systematic review synthesizes clinical data regarding CAR-T cells and bispecific antibodies for solid tumors and refractory malignancie…
Doctors are looking at new ways to use CAR-T cells and bispecific antibodies earlier in the treatment of hard-to-treat cancers.
Pseudoprogression in immune checkpoint inhibitor therapy is associated with modest tumor growth and early progression
Immune Checkpoint Inhibitors May Cause Initial Tumor Growth in Cancer
This meta-analysis of retrospective data examines patients with solid tumors experiencing pseudoprogression during immune checkpoint inhibit…
A growing tumor during immunotherapy might actually be a sign that the treatment is working, not a sign that the cancer is spreading.
cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer
Activating a cancer-fighting immune pathway can help tumors shrink but too much may backfire
This narrative review synthesizes evidence on cGAS–STING pathway activation in cancer. The authors report that heightened activity correlate…
Turning on a specific immune pathway helps some cancer patients survive longer, yet overactivating it can cause the immune system to stop wo…
T cell-based therapies show promise but face barriers in solid tumors
CAR-T and TIL therapies face hurdles in treating solid tumors
This narrative review examines CAR-T, TIL, and TCE therapies for hematologic and solid malignancies. Key challenges include on-target/off-tu…
A review notes that CAR-T, TIL, and TCE therapies struggle with tumor microenvironments and manufacturing issues for solid cancers.
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
Chemoimmunotherapy helps solid tumor patients, with or without liver metastases
This systematic review and meta-analysis evaluated 25915 patients with solid tumors receiving chemoimmunotherapy versus chemotherapy alone. …
For people with solid tumors, adding immunotherapy to chemo helps survival whether or not cancer has spread to the liver.
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
Meta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors
This systematic review and meta-analysis evaluated cadonilimab in patients with solid tumors, including gastric cancer and cervical non-smal…
A meta-analysis of 1,359 patients found cadonilimab combined with chemotherapy improved response rates and survival for solid tumors includi…
Review of BsAb-armed T cells for solid tumors and CAR-T and BsAb therapy
BsAb-armed T cells may help solid tumors fight back against cancer
This narrative review synthesizes evidence on BsAb-armed T cells (EATs) for solid tumors, comparing them to CAR-T and BsAb therapy. The auth…
New review suggests BsAb-armed T cells could improve tumor infiltration and reduce immune escape in solid tumors compared to standard CAR-T …
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.